DK3622953T3 - Kombinationsbehandling af cancer - Google Patents

Kombinationsbehandling af cancer Download PDF

Info

Publication number: DK3622953T3
Authority: DK; Denmark
Prior art keywords: cancer; combination therapy; therapy; combination
Prior art date: 2016-05-17

Application number

DK19205104.3T

Other languages

English (en)

Inventor

Palle Christophersen

Jan Stenvang

Annemette Thougaard

Nils Aage Brünner

Jens Lichtenberg

Original Assignee

Scandion Oncology As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-17

Filing date

2017-05-17

Publication date

2021-04-26

2017-05-17 Application filed by Scandion Oncology As filed Critical Scandion Oncology As

2021-04-26 Application granted granted Critical

2021-04-26 Publication of DK3622953T3 publication Critical patent/DK3622953T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK19205104.3T 2016-05-17 2017-05-17 Kombinationsbehandling af cancer DK3622953T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201670325		2016-05-17
EP17726573.3A EP3458052B1 (en)	2016-05-17	2017-05-17	Combination treatment of cancer

Publications (1)

Publication Number	Publication Date
DK3622953T3 true DK3622953T3 (da)	2021-04-26

Family

ID=58800797

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17726573.3T DK3458052T3 (da)	2016-05-17	2017-05-17	Kombinationsbehandling af cancer
DK19205104.3T DK3622953T3 (da)	2016-05-17	2017-05-17	Kombinationsbehandling af cancer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK17726573.3T DK3458052T3 (da)	2016-05-17	2017-05-17	Kombinationsbehandling af cancer

Country Status (19)

Country	Link
US (2)	US11103481B2 (da)
EP (3)	EP3622953B1 (da)
JP (1)	JP7033554B2 (da)
CN (4)	CN119548493A (da)
AU (1)	AU2017266724B2 (da)
BR (1)	BR112018073518A2 (da)
CA (1)	CA3023202A1 (da)
CY (2)	CY1122541T1 (da)
DK (2)	DK3458052T3 (da)
ES (2)	ES2770374T3 (da)
HR (2)	HRP20200076T1 (da)
HU (2)	HUE047542T2 (da)
LT (2)	LT3622953T (da)
PL (2)	PL3458052T3 (da)
PT (2)	PT3458052T (da)
RS (2)	RS61786B1 (da)
SI (2)	SI3622953T1 (da)
SM (2)	SMT202100245T1 (da)
WO (1)	WO2017198700A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3622953T1 (sl) *	2016-05-17	2021-05-31	Scandion Oncology A/S	Kombinirano zdravljenje raka
US11530181B2 (en)	2018-02-22	2022-12-20	University Of Florida Research Foundation, Incorporated	IL-6 inhibitors and methods of treatment
WO2020049139A1 (en) *	2018-09-06	2020-03-12	Scandion Oncology A/S	Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
WO2020079051A1 (en)	2018-10-16	2020-04-23	Scandion Oncology A/S	Compounds for treatment of microbial infection
CA3221558A1 (en)	2021-06-14	2022-12-22	Peter Michael Vestlev	Methods of increasing the plasma drug exposure of anticancer agents
EP4104834A1 (en)	2021-06-14	2022-12-21	Scandion Oncology A/S	Combination treatments for cancer patients and methods for identifying same
EP4355323A1 (en)	2021-06-14	2024-04-24	Scandion Oncology A/S	Combination treatments for cancer patients and methods for identifying same
TW202321205A (zh)	2021-07-16	2023-06-01	丹麥商斯坎丁腫瘤公司	Sco-101的熱力穩定形式
EP4197525A1 (en)	2021-12-20	2023-06-21	Scandion Oncology A/S	Combination of drugs for the treatment of cancer
CN117229258B (zh) *	2022-06-07	2024-07-19	杭州壹瑞医药科技有限公司	N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (en)	2022-06-14	2023-12-21	Scandion Oncology A/S	Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024013058A1 (en)	2022-07-11	2024-01-18	Scandion Oncology A/S	Salts of sco-101 and methods involving salts
WO2025125679A1 (en)	2023-12-15	2025-06-19	Scandion Oncology A/S	Improved anti-cancer treatment regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5004758A (en) *	1987-12-01	1991-04-02	Smithkline Beecham Corporation	Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
EP0977741B1 (en)	1997-04-22	2003-09-03	Neurosearch A/S	Substituted phenyl derivatives, their preparation and use
CN1263733C (zh)	1998-10-22	2006-07-12	神经研究公司	取代苯基衍生物,它们的制备和用途
CA2493253A1 (en) *	2002-08-01	2004-02-12	Neurosearch A/S	Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
JP2006527735A (ja)	2003-06-17	2006-12-07	ノイロサーチアクティーゼルスカブ	ジフェニル尿素誘導体、及びクロライドチャネル遮断剤としてのそれらの使用
EP1713809B1 (en)	2004-02-04	2009-07-29	Neurosearch A/S	Dimeric azacyclic compounds and their use
CA2591616A1 (en)	2004-12-17	2006-06-22	Neurosearch A/S	Diphenylurea derivatives useful as potassium channel activators
JP2009530238A (ja)	2006-03-14	2009-08-27	ノイロサーチアクティーゼルスカブ	ジフェニル尿素誘導体及び塩化物チャネル遮断薬又はＢＫＣａチャネル調節薬としてのその使用
PA8852901A1 (es) *	2008-12-22	2010-07-27	Lilly Co Eli	Inhibidores de proteina cinasa
TWI508954B (zh) *	2012-04-27	2015-11-21	Nat Defense Medical Ct	雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (en)	2014-03-10	2018-09-19	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	LRRC8 proteins and protein complexes and methods for identification of channel modulators
EP3064207B1 (en)	2015-03-04	2017-12-20	Scandion Oncology A/S	4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
SI3622953T1 (sl) *	2016-05-17	2021-05-31	Scandion Oncology A/S	Kombinirano zdravljenje raka

2017
- 2017-05-17 SI SI201730713T patent/SI3622953T1/sl unknown
- 2017-05-17 LT LTEP19205104.3T patent/LT3622953T/lt unknown
- 2017-05-17 CN CN202411725070.3A patent/CN119548493A/zh active Pending
- 2017-05-17 EP EP19205104.3A patent/EP3622953B1/en active Active
- 2017-05-17 CN CN202411725068.6A patent/CN119564679A/zh active Pending
- 2017-05-17 EP EP17726573.3A patent/EP3458052B1/en active Active
- 2017-05-17 HR HRP20200076TT patent/HRP20200076T1/hr unknown
- 2017-05-17 PT PT177265733T patent/PT3458052T/pt unknown
- 2017-05-17 PL PL17726573T patent/PL3458052T3/pl unknown
- 2017-05-17 BR BR112018073518-3A patent/BR112018073518A2/pt not_active Application Discontinuation
- 2017-05-17 SM SM20210245T patent/SMT202100245T1/it unknown
- 2017-05-17 DK DK17726573.3T patent/DK3458052T3/da active
- 2017-05-17 AU AU2017266724A patent/AU2017266724B2/en active Active
- 2017-05-17 JP JP2018560218A patent/JP7033554B2/ja active Active
- 2017-05-17 CA CA3023202A patent/CA3023202A1/en active Pending
- 2017-05-17 RS RS20210510A patent/RS61786B1/sr unknown
- 2017-05-17 HU HUE17726573A patent/HUE047542T2/hu unknown
- 2017-05-17 RS RS20200088A patent/RS59844B1/sr unknown
- 2017-05-17 EP EP21162597.5A patent/EP3854393A1/en active Pending
- 2017-05-17 WO PCT/EP2017/061823 patent/WO2017198700A1/en not_active Ceased
- 2017-05-17 HU HUE19205104A patent/HUE053744T2/hu unknown
- 2017-05-17 DK DK19205104.3T patent/DK3622953T3/da active
- 2017-05-17 PT PT192051043T patent/PT3622953T/pt unknown
- 2017-05-17 CN CN202411725073.7A patent/CN119548494A/zh active Pending
- 2017-05-17 LT LTEP17726573.3T patent/LT3458052T/lt unknown
- 2017-05-17 SM SM20200053T patent/SMT202000053T1/it unknown
- 2017-05-17 SI SI201730169T patent/SI3458052T1/sl unknown
- 2017-05-17 PL PL19205104T patent/PL3622953T3/pl unknown
- 2017-05-17 CN CN201780043536.3A patent/CN109475535A/zh active Pending
- 2017-05-17 US US16/302,195 patent/US11103481B2/en active Active
- 2017-05-17 ES ES17726573T patent/ES2770374T3/es active Active
- 2017-05-17 ES ES19205104T patent/ES2870805T3/es active Active
2020
- 2020-01-27 CY CY20201100070T patent/CY1122541T1/el unknown
2021
- 2021-04-09 HR HRP20210572TT patent/HRP20210572T1/hr unknown
- 2021-04-15 CY CY20211100332T patent/CY1124242T1/el unknown
- 2021-07-29 US US17/388,208 patent/US11903927B2/en active Active

Also Published As

Publication number	Publication date
EP3622953B1 (en)	2021-03-17
JP2019519506A (ja)	2019-07-11
CN119548494A (zh)	2025-03-04
EP3458052B1 (en)	2019-11-06
HRP20200076T1 (hr)	2020-04-03
HUE053744T2 (hu)	2021-07-28
HRP20210572T1 (hr)	2021-05-14
CY1122541T1 (el)	2021-01-27
HUE047542T2 (hu)	2020-04-28
CN109475535A (zh)	2019-03-15
ES2770374T3 (es)	2020-07-01
RS59844B1 (sr)	2020-02-28
DK3458052T3 (da)	2020-02-03
SMT202000053T1 (it)	2020-03-13
AU2017266724B2 (en)	2022-04-14
CA3023202A1 (en)	2017-11-23
JP7033554B2 (ja)	2022-03-10
US20210353596A1 (en)	2021-11-18
US11903927B2 (en)	2024-02-20
CN119564679A (zh)	2025-03-07
SI3622953T1 (sl)	2021-05-31
LT3622953T (lt)	2021-04-26
US20190269654A1 (en)	2019-09-05
EP3854393A1 (en)	2021-07-28
SMT202100245T1 (it)	2021-05-07
EP3622953A1 (en)	2020-03-18
ES2870805T3 (es)	2021-10-27
EP3458052A1 (en)	2019-03-27
US11103481B2 (en)	2021-08-31
RS61786B1 (sr)	2021-06-30
PL3458052T3 (pl)	2020-06-29
SI3458052T1 (sl)	2020-04-30
BR112018073518A2 (pt)	2019-03-19
PL3622953T3 (pl)	2021-08-16
CN119548493A (zh)	2025-03-04
CY1124242T1 (el)	2022-07-22
PT3622953T (pt)	2021-04-21
LT3458052T (lt)	2020-02-10
WO2017198700A1 (en)	2017-11-23
PT3458052T (pt)	2020-02-03
AU2017266724A1 (en)	2018-12-20

Publication	Publication Date	Title
EP3651772A4 (en)	2021-04-07	ANTI-CANCER POLYTHERAPY
PL3283527T3 (pl)	2021-06-14	Leczenie skojarzone nowotworów
EP3463464A4 (en)	2020-07-01	ASSOCIATION TREATMENT
DK3622953T3 (da)	2021-04-26	Kombinationsbehandling af cancer
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
IL255261A0 (en)	2017-12-31	Methods for treating cancer
HUE059694T2 (hu)	2022-12-28	Készítmény rák kezelésére
IL263802A (en)	2019-01-31	Cancer treatment combinations
DK3033086T3 (da)	2022-01-03	Kombinationsterapi til behandling af cancer
DK3851537T3 (da)	2024-03-18	Behandling af hyperbilirubinæmi
DK3439635T3 (da)	2021-03-08	Formuleringer til behandling af fast tumor
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3518932T3 (da)	2025-01-27	Behandling af prostatacancer
DK3525774T3 (da)	2022-03-14	Lasofoxifen behandling af er+ brystcancer
EP3413927A4 (en)	2019-11-27	CANCER THERAPY
IL268463A (en)	2019-09-26	Cancer treatment
DK3400072T3 (da)	2021-03-22	Formuleringer til behandling af blærecancer
DK3307267T3 (da)	2019-07-01	Behandling af multipel sklerose
DK3532076T3 (da)	2021-05-31	Immunterapeutiske behandlinger af tumorer
DK3408265T3 (da)	2020-06-02	Terapeutiske forbindelser
DK3468604T3 (da)	2021-04-19	Farmaceutiske kombinationer til behandling af cancer
EP3576791A4 (en)	2020-11-25	CALRETICULIN-MEDIATION CANCER TREATMENT
IL262851A (en)	2018-12-31	Combination prime: boost therapy
DK3393478T3 (da)	2020-03-23	Kombinationsterapi
DK3297619T3 (da)	2022-08-15	Terapeutiske anvendelser af L-4-chlorkynurenin